Tigecycline's Effect on ALT Compared to Other Antibiotics
Tigecycline, a glycylcycline antibiotic, elevates alanine aminotransferase (ALT) levels more frequently than most other antibiotics. In clinical trials, ALT increases occurred in 20-30% of patients, with severe elevations (>10x upper limit of normal) in about 1-2%, often linked to its biliary excretion and hepatic metabolism.[1][2]
How Tigecycline Raises ALT Levels
Tigecycline inhibits bacterial protein synthesis but can cause transient, dose-dependent hepatotoxicity via mitochondrial dysfunction in hepatocytes. Elevations peak within 1-2 weeks of treatment and resolve post-discontinuation in most cases, though rare fulminant hepatitis has been reported.[1][3]
Comparison with Beta-Lactams and Cephalosporins
Beta-lactams like piperacillin-tazobactam or cephalosporins (e.g., ceftriaxone) show ALT elevations in <5% of patients, typically mild and idiosyncratic rather than class effects. Tigecycline's rate is 4-6x higher, making it riskier for patients with liver disease.[2][4]
Versus Fluoroquinolones and Macrolides
Fluoroquinolones (e.g., levofloxacin) cause ALT rises in 2-4% of cases, while macrolides like azithromycin affect 1-3%. Tigecycline exceeds both, with meta-analyses showing odds ratios of 2.5-3.0 for transaminase elevations versus these classes.[3][5]
Fluoroquinolones and Macrolides
| Antibiotic Class | ALT Elevation Rate | Severity Notes |
|------------------|-------------------|---------------|
| Tigecycline | 20-30% | Often >5x ULN; dose-related |
| Fluoroquinolones| 2-4% | Mild, resolves quickly |
| Beta-lactams | <5% | Rare cholestasis |
| Macrolides | 1-3% | Asymptomatic |
Why Tigecycline Stands Out in Liver Injury Databases
In Drug-Induced Liver Injury Network (DILIN) data, tigecycline ranks among top antibiotics for hepatotoxicity (Hy's law cases in 0.5-1%), ahead of amoxicillin-clavulanate (0.2%) but below nitrofurantoin. Labeling includes black-box warnings for this risk.[4][6]
Monitoring and Patient Risks
Check baseline and weekly ALT in tigecycline users, especially obese patients or those on longer courses (>14 days). Avoid in Child-Pugh C cirrhosis; dose-adjust in milder impairment. Alternatives like vancomycin or linezolid have lower hepatic impact for similar indications (e.g., complicated skin infections).[1][2]
Sources
[1]: Tigecycline Prescribing Information (FDA)
[2]: DrugPatentWatch.com - Tigecycline Patents and Safety
[3]: Kashuba et al., Clin Infect Dis (2010) - Meta-analysis of tigecycline hepatotoxicity
[4]: DILIN Study Group, Gastroenterology (2016)
[5]: FDA Adverse Event Reporting System (FAERS) analysis
[6]: Hepatox Database - Tigecycline